ReviewBeilstein journal of nanotechnology2019
Targeting strategies for improving the efficacy of nanomedicine in oncology.
Review in Beilstein journal of nanotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 66 citations in OpenAlex.
- Smart mesoporous silica nanoparticles for precision cancer therapy: Tumor targeting and stimuli-responsive controlled release.Smart molecules : open access · 2026Review
- The protein corona at the nano-bio interface: the need for standardized methodology and opportunities for neurodegenerative disease intervention.RSC advances · 2026Review
- Nanoparticles in the Treatment of Renal Fibrosis.International journal of nanomedicine · 2026Review
- Development of Curcumin-Loaded Hybrid Lipid-Polymeric Nanoparticles for Hypoxia-Related Applications.International journal of nanomedicine · 2026Article
- Next-generation Mesoporous Silica Nanoparticles: Precision-engineered Platforms for Ovarian Cancer Therapy.Current drug research reviews · 2026Review
- Beyond borders: engineering organ-targeted immunotherapies to overcome site-specific barriers in cancer.Drug delivery and translational research · 2025Review
- Silicasomes in Oncology: From Conventional Chemotherapy to Combined Immunotherapy.Molecules (Basel, Switzerland) · 2025Review
- Current Advances in Nanocarriers for Cancer Therapy.International journal of nanomedicine · 2025Review
- Zwitterionic Amino-Acid-Derived Polyacrylamides with a Betaine Twist - Synthesis and Characterization.Macromolecular rapid communications · 2025Article
- Amino-Acid-Derived Anionic Polyacrylamides with Tailored Hydrophobicity-Physicochemical Properties and Cellular Interactions.ACS polymers Au · 2024Article
- Dual-functionalized architecture enables stable and tumor cell-specific SiOBeilstein journal of nanotechnology · 2024Article
- Metal nanoparticles as a potential technique for the diagnosis and treatment of gastrointestinal cancer: a comprehensive review.Cancer cell international · 2023Review
- Recent Advances in Green Metallic Nanoparticles for Enhanced Drug Delivery in Photodynamic Therapy: A Therapeutic Approach.International journal of molecular sciences · 2023Review
- Anti-COVID-19 Nanomaterials: Directions to Improve Prevention, Diagnosis, and Treatment.Nanomaterials (Basel, Switzerland) · 2022Review
- Nanomaterial Probes for Nuclear Imaging.Nanomaterials (Basel, Switzerland) · 2022Review
- Advances in lipid-based nanocarriers for breast cancer metastasis treatment.Frontiers in medical technology · 2022Review
- Novel Strategies for Nanoparticle-Based Radiosensitization in Glioblastoma.International journal of molecular sciences · 2021Review
- Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics.Cancer drug resistance (Alhambra, Calif.) · 2021Review
- Supramolecular lipid nanoparticles as delivery carriers for non-invasive cancer theranostics.Current research in pharmacology and drug discovery · 2021Review
- Conventional Nanosized Drug Delivery Systems for Cancer Applications.Advances in experimental medicine and biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of nanoparticles as drug carriers has provided a powerful weapon in the fight against cancer. These nanocarriers are able to transport drugs that exhibit very different nature such as lipophilic or hydrophilic drugs and big macromolecules as proteins or RNA. Moreover, the external surface of these carriers can be decorated with different moieties with high affinity for specific membrane receptors of the tumoral cells to direct their action specifically to the malignant cells. The selectivity improvement yielded by these nanocarriers provided a significative enhancement in the efficacy of the transported drug, while the apparition of side effects in the host was reduced. Additionally, it is possible to incorporate targeting moieties selective for organelles of the cell, which improves even more the effect of the transported agents. In the last years, more sophisticated strategies such as the use of switchable, hierarchical or double targeting strategies have been proposed for overcoming some of the limitations of conventional targeting strategies. In this review, recent advances in the development of targeted nanoparticles will be described with the aim to present the current state of the art of this technology and its huge potential in the oncological field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.